In the claims:

Please amend the claims as follows:

1. (Currently Amended) A cyclosporin represented by the formula



(1)

wherein

A is



X is absent, -C1-C6 alkyl-, or –C3-C6 cycloalkyl-

Y is selected from the group consisting of:

(i) C(O)-O-R1, where R1 is hydrogen, C1-C6 alkyl, which is ~~optionally~~ substituted with halogen, heterocyclic, aryl, C1-C6-alkoxy, C1-C6 alkylthio, halogen-substituted C1-C6 alkoxy,or halogen-substituted C1-C6 alkylthio;

(ii) C(O)-S-R1, where R1 is as previously defined;

(iii) C(O)-OCH2-OC(O)R2, where R2 is C1-C6 alkyl, optionally substituted with halogen, C1-C6 alkoxy, C1-C6 alkylthio, heterocyclic or aryl;

(iv) C(S)-O-R1, where R1 is as previously defined, and

(v) C(S)-S-R1, where R1 is as previously defined;

B is –αAbu-, -Val-, -Thr- or –Nva-; and

U is –(D)Ala-, -(D)Ser-, –[O-(2-hydroxyethyl)(D)Ser]-, -[O-acyl(D)Ser]- or -[O-(2-acyloxyethyl)(D)Ser]-;

or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) A cyclosporin according to claim 1 wherein B is –αAbu-, and U is –(D)Ala-.

a18 Cont.

3 (Currently Amended) A cyclosporin according to claim 1, wherein B is –αAbu-, U is –(D)Ala-,

X is absent, and Y is selected from a group consisting of:

C(O)-O-R1 where R1 is hydrogen, C1-C6 alkyl, which is ~~optionally~~ substituted with halogen, heterocyclic, aryl, C1-C6-alkoxy, C1-C6-alkylthio, halogen-substituted C1-C6 alkoxy,or halogen-substituted C1-C6 alkylthio;

C(O)-S-R1 where R1 is as previously defined

C(O)-OCH_2-OC(O)R2 where R2 is C1-C6 alkyl, optionally substituted with halogen, C1-C6-alkoxy, C1-C6-alkylthio, heterocyclic or aryl

4. (Currently Amended) A cyclosporin according to claim 1 which is selected from the group consisting of:

~~Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = COOCH3~~

~~Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = COOH~~

~~Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = COOEt~~

~~Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = COOCH2CH2CH3~~

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = ~~COOCH2Ph~~ $COOCH_2Ph$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = ~~COOCH2F~~ $COOCH_2F$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = ~~COOCHF2~~ $COOCHF_2$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = ~~COOCF3~~ $COOCF_3$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = ~~COOCH2CF3~~ $COOCH_2CF_3$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = ~~COOCH2Cl~~ $COOCH_2Cl$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = ~~COOCH2OCH3~~ $COOCH_2OCH_3$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = ~~COOCH2OCH2CH2OCH3~~ $COOCH_2OCH_2CH_2OCH_3$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = ~~C(O)SCH2Ph~~ $C(O)SCH_2Ph$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is ~~–CH2CH2CH2–~~ – $CH_2CH_2CH_2$-, Y = ~~COOCH3~~ $COOCH_3$; and

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = COOFmoc.

5. (Original) A process for preparing a cyclosporin compound represented by formula I as defined in claim 1, comprising reacting a compound of formula 1 wherein A= -MeBmt- and B and U are as defined in claim 1 with an olefin represented by the formula CH2=CH-X-Y, wherein X and Y are as defined in claim 1, with a catalyst in the presence of a lithium salt in an organic solvent.

6. (Original) The process as defined in claim 5 wherein said catalyst is Grubb's ruthenium alkylidene catalyst, Nolan's catalyst, a benzylidene catalyst or a molybdenum catalyst.

7. (Original) The process as defined in claim 5 wherein the reaction is carried out at from room temperature to about 100 ^{0}C for 1 to 7 days.

8. (Original) A pharmaceutical composition for topical administration comprising a cyclosporin compound of claim 1 together with a pharmaceutically acceptable diluent or carrier therefor.

9. (Original) A method for treating inflammatory or obstructive airways disease in a subject in need of said treatment, which comprises topically administering to said subject a therapeutically effective amount of a cyclosporin compound of claim 1.

10. (Original) The method of claim 9 wherein said step of topically administering is by inhalation.

11. (Original) The method of claim 9, wherein said airways disease is asthma, allegic rhinitis, bronchitis, COPD, chronic bronchitis or cystic fibrosis.